Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Two Classes of Fibroblasts Inhabit the Synovial Membrane in RA

By Gerald M. Slutzky, PhD
Posted on 07 Dec 2016
Rheumatoid arthritis researchers have identified two distinct classes of synovial fibroblasts (SFs) differentiated by expression of either PDPN (podoplanin) or CD248 (endosialin), which were located within different anatomical compartments of the inflamed synovial membrane.

Investigators at the University of Birmingham (United Kingdom) studied two distinct SF populations that were located preferentially in the lining or sub-lining layers of the synovial membrane, which were defined by their expression of either PDPN or CD248, and explored their ability to undergo self-assembly and transmigration in vivo.

For this study SFs were cultured in vitro, and phenotypic changes following stimulation with interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and transforming growth factor (TGF)-beta1 were evaluated. More...
To examine the phenotype of SF in vivo, a severe combined immunodeficiency (SCID) human-mouse model of cartilage destruction was utilized.

Results published in the November 18, 2016, online edition of the journal Arthritis Research and Therapy revealed that SFs in the lining layer in rheumatoid arthritis expressed high levels of PDPN compared to the normal synovium, whereas CD248 expression was restricted to sub-lining layer cells. TNF-alpha or IL1 stimulation in vitro resulted in an increased expression of PDPN. In contrast, stimulation with TGF-beta1 induced CD248 expression. The PDPN-expressing cells were associated with early fibroblast migration and cartilage erosion.

In the SCID human-mouse model, rheumatoid SF recapitulated the expression of PDPN and CD248. Thus, fibroblasts adjacent to cartilage expressed PDPN, and attached to, invaded, and degraded cartilage. Since PDPN-expressing cells were associated with early fibroblast migration and cartilage erosion in vivo, the investigators proposed that PDPN-expressing cells may be an attractive therapeutic target in rheumatoid arthritis.

First author Dr. Adam Croft, researcher in the rheumatology research group at the University of Birmingham, said, "This study not only shows the existence of distinct sub-sets of synovial fibroblasts, but also suggests that these cells are able to self-organize into lining and sub-lining layers in the presence of cartilage. Combined with the difference in migration rates between the two types of cell, these results are extremely promising in terms of finding new therapeutic targets for treatment of rheumatoid arthritis."

Related Links:
University of Birmingham


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.